Bioxcel Therapeutics shares rise 1.34% premarket after positive FDA comments on BXCL501 for agitation in bipolar disorder or schizophrenia.

Bioxcel Therapeutics, Inc. rose 1.34% in premarket trading, with the company announcing positive FDA comments from a pre-sNDA meeting for BXCL501 in agitation associated with bipolar disorder or schizophrenia. Additionally, the company reported a database lock in the SERENITY At-Home Phase-3 study for safety in acute agitation associated with bipolar disorder or schizophrenia.